MOSAIC
2004
FOLFOX as Adjuvant Therapy in Stage II/III Colon Cancer
In 2,246 patients with resected stage II/III colon cancer, adjuvant FOLFOX4 improved disease-free survival compared with 5-FU/leucovorin.
Result
Efficacy: 3-year disease-free survivalHR 0.77 · P = 0.002
Below 1 favours FOLFOX4, above 1 favours 5-FU/leucovorin.
- Absolute difference
- 5.3 points
- NNT
- 19
Absolute difference and NNT are derived from the event rates.
Also reported: 6-yr OS in stage III 72.9% vs 68.7% (HR 0.80, 95% CI 0.65-0.97, P=0.023); no OS benefit in stage II.
- Subtopic
- Colon adjuvant
- Design
- Open-label RCT
- Relevance
- Practice-defining: a trial the field needs to know.
- Source
- André T, et al. N Engl J Med. 2004;350(23):2343-2351; André T, et al. J Clin Oncol. 2009;27(19):3109-3116.doi 10.1056/NEJMoa032709
Discussion & critique
Established oxaliplatin-based adjuvant therapy in stage III colon cancer. Stage II remains case-by-case, weighted by clinical and molecular risk features.